Influenza diagnostics market seen reaching $3.53B by 2035

Market Research Future projects the global influenza diagnostics market will rise from $1.94 billion in 2025 to $3.53 billion by 2035, driven by molecular testing adoption, government surveillance funding and growth in at-home and point-of-care testing. The outlook points to a faster shift away from legacy antigen and culture-based methods as flu testing moves into retail, telehealth and decentralized care settings.

Why it matters: - Influenza diagnostics are becoming a bigger part of pandemic preparedness, seasonal surveillance and decentralized care. - The market’s growth reflects a shift toward faster, more sensitive testing across hospitals, pharmacies and point-of-care settings. - The expansion also benefits vendors with molecular platforms, consumables and automated workflows.

What happened: - Market Research Future projected the global influenza diagnostics market will grow from $1.94 billion in 2025 to $3.53 billion by 2035. - The forecast implies a 6.15% compound annual growth rate from 2026 to 2035. - The market is expected to reach $2.06 billion in 2026 as the forecast period begins. - The report said growth is being driven by molecular platform migration, government surveillance funding and adoption of at-home and point-of-care tests. - Market Research Future also published a sample request page and a customization request page for the report. Request a free sample and ask for customization.

The details: - RT-PCR, LAMP and CRISPR-based assays are replacing legacy culture-based and antigen testing in many settings. - Molecular platforms are described as delivering sensitivity above 95%, compared with 50% to 70% for lateral-flow antigen devices. - Molecular testing is also cutting hospital turnaround times by 40% to 60% and can return results in under 60 minutes. - The U.S. CDC allocates more than $900 million annually for influenza monitoring and vaccine strain selection. - The WHO Global Influenza Surveillance and Response System coordinates data from 148 national influenza centers. - The European Commission earmarked EUR 220 million under Horizon Europe in 2024 for respiratory pathogen surveillance. - The U.S. Hospital Preparedness Program allocated $385 million in 2024 for laboratory modernization, including molecular influenza testing. - RT-PCR generated $0.54 billion in revenue in 2025. - CRISPR-based assays are projected to grow at a 10.0% CAGR through 2035 and are positioned as lower-cost alternatives to RT-PCR. - Rapid influenza diagnostic tests held 44.0% of the market in 2025. - Hospitals and clinical laboratories held 45.0% of end-user revenue in 2025. - Point-of-care settings are forecast to grow at a 9.85% CAGR to 2035. - Independent diagnostic laboratories generated $0.37 billion in 2025 revenue. - North America accounted for about 40.0% of global revenue in 2025. - Europe held about 27.5% of global revenue in 2025. - Asia-Pacific represented 22.0% of global revenue in 2025 and is forecast to grow at 8.40% CAGR from 2026 to 2035. - South America held about 5.5% of global revenue in 2025. - The Middle East and Africa held about 5.0% of global revenue in 2025. - The top five players are expected to hold 55% to 60% of revenue, with the market moderately concentrated. - Roche Diagnostics, Abbott Laboratories, QuidelOrtho, Hologic, bioMérieux, Becton, Dickinson and Company, and Cepheid are among the named leading companies.

Between the lines: - The report signals a market moving from basic flu detection to broader respiratory testing and workflow automation. - Government funding is not just supporting surveillance; it is helping establish reimbursement and procurement patterns that favor molecular tools. - AI-enabled lab automation could widen the gap between larger hospital networks and smaller labs that still depend on cheaper antigen tests. - Consumer self-testing, including over-the-counter flu/COVID combination tests, is shifting testing volume into retail channels and telehealth-linked care. - The company said lower manufacturing costs could bring lateral-flow and CRISPR-based devices below $5 per unit by 2028, which could expand adoption in middle-income markets.

What's next: - CRISPR-based assays are expected to be the fastest-growing test type through 2035. - High-volume laboratories are expected to adopt AI-driven sorting and result interpretation more widely by 2030. - Multiplex panels that test for influenza, COVID-19, RSV and strep on one cartridge could represent more than 30% of all influenza tests globally by 2032. - India plans to equip 12,000 primary health centers with rapid molecular testing capability by 2028, which could create a new growth wave in Asia-Pacific. - Retail pharmacies, e-commerce platforms and telehealth pathways are likely to capture a larger share of influenza test demand as consumer self-testing grows.

The bottom line: - Influenza diagnostics are moving toward a molecular, decentralized and AI-supported model, with government surveillance spending and consumer testing likely to keep the market growing through 2035.